Endomag
Cambridge
About Endomag
Endomag is a medical technology company devoted to improving the global standard of cancer care. The company's Sentimag probe, Magseed marker, and Magtrac node marker are already in use by many of the world’s leading physicians and cancer centers. Endomag's goal is to help women with breast cancer avoid surgery when it isn’t needed, and experience better outcomes when it is. As of 2019, the company has already helped 70,000+ women around the world access more precise and less invasive breast cancer care. Founded in 2007 as a spin-out from the University of Houston and the University College London (UCL), Endomag continues to develop its unique clinical platform from its headquarters in Cambridge, United Kingdom. The company sells its products through a network of distributors in Europe, the Middle East, Africa, and Australasia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $39.8M
- Funding stage: M&A
- Last round: Series D (Nov 2020)
- Website: endomag.com
- Phone: +44 1223 652540
Industries & Categories
Health Care, Information Technology, Medical, Medical Device, Oncology
Social Profiles
Canonical: https://fsome.com/organization/endomag-36921 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.